title: Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
abstract: BACKGROUND
  Virulence factors of Helicobacter pylori are associated with peptic ulcer disease and may be also associated with the efficacy of treatment.
  
  
  OBJECTIVE
  To determine the relation between the vacA and the cagA status of H pylori, clinical disease, and treatment outcome.
  
  
  METHODS
  121 patients with H pylori infection and peptic ulcer disease or functional dyspepsia were treated by quadruple antibiotic therapy in two groups for one and two days, respectively.
  
  
  METHODS
  DNA was isolated from gastric antral biopsy specimens, taken before and after treatment, and the vacA and cagA status was determined by polymerase chain reaction and reverse hybridisation.
  
  
  RESULTS
  Peptic ulcer disease was significantly associated with the vacA s1 type, and cagA positivity, but not with the vacA m type. Treatment efficacy was significantly higher in patients with peptic ulcer disease, or infected with cagA+/vacA s1 strains.
  
  
  CONCLUSIONS
  The strong association between the cagA and vacA status and peptic ulcer disease was confirmed. Cure rates seem to be higher for patients with cagA+/vacA s1 H pylori strains, which is consistent with the higher cure rate observed among ulcer patients compared with functional dyspepsia patients. Therefore, treatment studies may require stratification for presence of ulcers as well as H pylori genotypes.
authors.affiliation: Delft Diagnostic Laboratory, Delft, The Netherlands.
authors.forename: L J
authors.initials: LJ
authors.lastname: van Doorn
authors.forename: P M
authors.initials: PM
authors.lastname: Schneeberger
authors.forename: N
authors.initials: N
authors.lastname: Nouhan
authors.forename: A P
authors.initials: AP
authors.lastname: Plaisier
authors.forename: W G
authors.initials: WG
authors.lastname: Quint
authors.forename: W A
authors.initials: WA
authors.lastname: de Boer
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D016481:Helicobacter Infections / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy*; D012044:Regression Analysis; D013752:Tetracycline / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D064747:Lansoprazole; D008795:Metronidazole; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole